ALFA Finder| Revenue growth | 40.08% YoY for FY26; 27.27% for Q4 FY26. |
|---|---|
| Margins | EBITDA margin improved to 14.83% in FY26; expanding due to scale. |
| Order book | 6 to 7 months of orders always in hand. |
| Demand visibility | Strong; orders in hand upwards of ₹320-330 crores. |
| Management confidence | High; history of under-promising and over-delivering on guidance. |
Growth
FY26 total income grew 40.08% to ₹639.12cr; EBITDA grew 72.05% to ₹94.79cr; PAT grew 59.59% to ₹33.21cr.
Outlook
Guided 25-30% topline growth for FY27; targeting 10-12% PAT margins in next few years as demographics reach scale.
Risks
Geopolitical tensions affecting raw material costs, though currently mitigated by buffer stocks and 6-7 month order visibility.
Last quarter's promises, checked
Delivered
- Guided 15-20% vintage business growth → delivered 15-20% (= BEAT)
- Guided 12-18 month fund sufficiency → no immediate fund raise needed (= BEAT)
- Guided FY26 revenue ~₹550-580cr → delivered ₹639.12cr (= BEAT)
Partly delivered
- Guided 5-6% PAT margin → delivered 5.2% (= PARTIAL)
Earnings Call filed with BSE, NSE: FREDUN. Summary written with AI assistance from the document.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,506.55
- Market cap
- ₹2,159 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 40.8×Sector 43.8×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Q2 FY27 Results: Net Profit ₹18.6 Cr, Up 97.9% YoY
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹265.9 Cr (+85.2% YoY) and net profit of ₹18.6 Cr (+97.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.6 Cr · +97.9% YoY
Fredun Pharmaceuticals Board Meeting Date
Fredun Pharmaceuticals will hold a board meeting on 05 November 2026 to consider half-year results. Trading window stays closed until 48 hours after results.
Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.